Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 826 participants.
Also called NCT02983214
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose health services research
- Phase
- Phase 4
- Enrolled
- 826 participants
- Sponsor
- Registry
-
NCT02983214
-
- Other papers using this trial's data
- Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Greece
- Registry status
- Completed
Technical summary
Registry record NCT02983214. Randomized; no masking; primary purpose health services research. Start 2016-11 (actual); primary completion 2019-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
- Acronym
- DORIC
- Condition
- Ischemic Stroke
- Condition
- Peripheral Artery Disease
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Cilostazol
- Lead sponsor
- University of Ioannina
- Collaborator
- LIBYTEC Pharmaceutical S.A.
Record details
- Record id
cardio:ct-nct02983214- Content hash
4189cd70a0c78927a4fec37ba9223639062b35388d9ea1a5dece9f5509311c93